The Lymphoma Service at Roswell Park follows the Clinical Practice Guidelines in Oncology™ — the National Comprehensive Cancer Network’s internationally recognized guidelines for treating different types of cancer. They are the most comprehensive, most frequently updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines are developed by panels of leading experts, including Myron Czuczman, MD (Non-Hodgkin Lymphoma Panel), and Francisco Hernandez-Ilizaliturri, MD (Hodgkin Lymphoma Panel).
The Lymphoma Team diagnoses and treats patients with cancers of the blood, including:
Because there are many subtypes of lymphoma, seeking care from a team that specializes in lymphoma is essential. Every member of the Roswell Park Lymphoma Team has extensive subspecialty experience in diagnosing and treating lymphoma.
Treatment guidelines are critical, because treatments can vary widely for different lymphoma subtypes. They may include:
Sometimes a combination of treatments works best. The choice of treatment depends mainly on the following:
In recent years, therapies that zero in on specific molecules found only on cancer cells — drugs called targeted therapies — have transformed treatment plans for many lymphoma patients. Roswell Park investigators have conducted groundbreaking research on targeted therapies for lymphoma and continue to offer clinical research studies (clinical trials) of these and other new lymphoma treatments, giving our patients access to these options before they are available at most other centers. Clinical research studies based on the latest scientific research offer great hope for improving outcomes for lymphoma patients.